Business
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p","length":167,"tagName":"div"}]